Array reports more revenue, less loss

BOULDER – Drug development company Array BioPharma Inc. reported an increase in revenue and a lower second-quarter loss.

Boulder-based Array (Nasdaq: ARRY) posted a net loss of $3.8 million, or 6 cents a share, for the three-month period ended Dec. 31. That loss was smaller than the $12.4 million net loss, or 23 cents per share for the same period a year earlier. Revenue totaled $23.2 million, up from the $16.5 million for the same period a year earlier.

Array has several clinical drug development programs at the moment, which focus on drugs to treat cancer, pain and asthma, among others. In…